Hear experts Eugene Kennedy, $APRE CMO, Dr. Alex Spira, of Virginia Cancer Specialists Research Institute and NEXT Oncology, and Kevin DeGeeter of @LadenburgLTS discuss the science, clinical and market potential of WEE1 inhibition, moderated by @SolomonsWisdom: bit.ly/4yVw7Fr

The replay of our “State of WEE1 Inhibition in Precision Oncology” is now available. Moderated by @SolomonsWisdom, the panel explored WEE1 inhibition’s emerging role in precision oncology with experts across clinical and equity research. bit.ly/4yVw7Fr $APRE

Today at 11 AM ET, join $APRE Chief Medical Advisor, Dr. Eugene Kennedy, and leading experts for a pre-#ESMO2026 virtual panel exploring the evolving WEE1 inhibitor landscape. Register for “The State of WEE1 Inhibition in Precision Oncology”: bit.ly/4yVw7Fr

Tomorrow: Join Aprea at 11:00 AM ET for “The State of WEE1 Inhibition in Precision Oncology,” a pre-ESMO virtual panel featuring experts in oncology and biotechnology. Register here: bit.ly/4yVw7Fr #ESMO2026 $APRE

Join Aprea on Tuesday, Oct. 20 at 11 AM ET for a pre-#ESMO2026 virtual panel covering WEE1's biology, the selectivity challenge that has shaped the class, and what to watch in the months ahead, across scientific, clinical, and market perspectives. Register: bit.ly/3Wwbf9d $APRE

This week, CEO Oren Gilad participated in a panel at the 2026 Maxim Growth Summit, joining fellow leaders to discuss innovation and the development of new treatment options for patients. Thank you to @MaximGrp for hosting this engaging discussion. $APRE

Oren Gilad, Ph.D., CEO of Aprea, will participate in a fireside chat tomorrow, Tuesday, October 14 at 9:00 a.m. ET, at the 2026 @MaximGrp Growth Summit in New York City. For details: bit.ly/4rPCGGO $APRE

Aprea will participate in a panel discussion at the #PABC Regional Biotechnology Conference 2026 on October 15th, from 9:00 a.m. to 12:00 p.m. ET at the Pennsylvania Biotechnology Center in Doylestown, PA. For details: bit.ly/4rPCGGO $APRE

Aprea CEO Oren Gilad joined NanoCap Podcast to discuss targeted cancer therapies, the science behind synthetic lethality, and Aprea’s latest clinical progress. Hear how innovative approaches could help advance new treatment options for patients: bit.ly/478AikZ $APRE

Oren Gilad Ph.D., President and CEO, will participate in the 2026 @MaximGrp Growth Summit, to take place October 12-14 in NYC and the #PABC Regional Biotechnology Conference, to take place October 15 in Doylestown, PA. For details, visit: bit.ly/4rPCGGO $APRE

“We look forward to presenting an update from our ongoing Phase 1 ACESOT-1051 trial at the EORTC-NCI-AACR Symposium and sharing these data with the international oncology community,” said Oren Gilad, Ph.D., President and CEO of Aprea. Read more: bit.ly/3TK8UXl $APRE

An abstract featuring updated interim results from Aprea's ongoing Ph.1 ACESOT-1051 study of WEE1 inhibitor APR-1051 in advanced solid tumors has been accepted for oral presentation at the 38th #ENAsymp26, on Nov. 18-20, in Spain. bit.ly/3TK8UXl $APRE

“The first thing I could say to a newly diagnosed cancer patient is that there’s hope.” $APRE CEO Oren Gilad, Ph.D. joined @chrisleidli on #RxforBiotech to discuss precision oncology, synthetic lethality, and the science behind our investigational therapies. bit.ly/4ix6Dc7

A webcast of Aprea President and CEO Oren Gilad, Ph.D.'s presentation at the @HCWCO 28th Annual Global Investment Conference is now available. Tune-in here: bit.ly/4yBbqhc $APRE

In a recent interview with GEN, Oren Gilad, Ph.D., Aprea’s President and CEO, said the early clinical activity data from our WEE1 inhibitor, APR-1051, marks an important moment for the program. As Gilad stated in the interview, "We saw tumor shrinkage and very tolerable side effects." Building on this momentum, the company is accelerating enrollment and expanding the development of APR-1051 into additional biomarker-defined tumor populations and combination settings. Read more about APR-1051 and what’s next in this new feature from @GENbio: bit.ly/4hfQM0n $APRE

“You have to build this thing one brick at a time.” In a new interview with @ClinicalLeader1, Aprea Chief Medical Advisor, Eugene Kennedy, MD, shares how Aprea is taking an intentional approach to the clinical development of APR-1051, from identifying the patients most likely to benefit to planning for future combination strategies. Read the full article: bit.ly/3VovWmU $APRE

Oren Gilad, Ph.D., President and CEO of Aprea Therapeutics, will present at the H.C. Wainwright 28th Annual Global Investment Conference, to be held September 14-16, 2026. For details, visit: bit.ly/3UKOCgx $APRE

Oren Gilad, Ph.D., Aprea’s President and CEO, recently spoke with @GENbio about the progress we’re making across our clinical programs. The conversation highlighted the early clinical activity observed with our WEE1 inhibitor, APR-1051, and what’s next as we expand enrollment and development into additional biomarker-defined tumor populations and combination settings. Oren also shared an update on our conversations with leading academic centers for ATRN-119, our ATR inhibitor. Read more about Aprea’s clinical momentum in the full article: bit.ly/4hfQM0n $APRE

“Our expanding patent portfolio reflects Aprea’s commitment to innovation and building a differentiated leadership position in precision medicine,” said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. Read more: bit.ly/4qGcHkD $APRE

Aprea today announced the expansion of its intellectual property portfolio for precision oncology programs, which includes 28 issued and 30 pending patents. Read more: bit.ly/4qGcHkD $APRE